Ponatinib (Everest)

Product Overview

Ponatinib (Brand name: ICLUSIG) manufactured by Everest Pharma is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI). On December 14, 2012, Ponatinib received accelerated approval from the U.S. FDA for the treatment of chronic myeloid leukemia (CML) with the ABL T315I mutation and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

It is also indicated for patients with CML or Ph+ ALL who are resistant to or intolerant of prior tyrosine kinase inhibitor therapies.

Although first- and second-generation TKIs significantly improved outcomes for patients with CML and Ph+ ALL, resistance still developed in some patients with BCR-ABL mutations, particularly the T315I mutation. Before the approval of Ponatinib, no available TKIs were capable of overcoming resistance associated with these mutations.

Clinical studies demonstrated major hematologic response rates of:

• 55% in accelerated-phase CML
• 31% in blast-phase CML
• 41% in Ph+ ALL patients

These findings established Ponatinib as a powerful oral TKI and an important therapeutic option for patients with difficult-to-treat CML, especially those carrying T315I mutations.

📊 Clinical Evaluation

In the PACE trial, outcomes of patients treated with Ponatinib monotherapy were retrospectively compared with allogeneic stem cell transplantation (allo-SCT) data from the European Bone Marrow Transplant Registry.

Kaplan-Meier survival analysis and multivariable Cox proportional hazards models were used to compare overall survival (OS), adjusting for:

• Time from diagnosis to intervention
• Age
• Gender
• Geographic region

The study reported 24-month and 48-month overall survival rates as well as median overall survival data across different CML phases and Ph+ ALL populations.

📌 Indications

Ponatinib is indicated for adult patients with:

• Chronic-phase CML
• Accelerated-phase CML
• Blast-phase CML
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

who are resistant to or intolerant of previous tyrosine kinase inhibitor treatment.

💊 Dosage and Administration

• Recommended dose: 45 mg orally once daily
• May be taken with or without food
• Treatment should continue as long as there is no evidence of disease progression or unacceptable toxicity

Dose interruption, reduction, or discontinuation may be required for hematologic or non-hematologic toxicities.

⚠️ Common Adverse Reactions

Non-Hematologic Side Effects (≥20%)

• Hypertension
• Rash
• Abdominal pain
• Fatigue
• Headache
• Dry skin
• Constipation
• Joint pain
• Nausea
• Fever

Hematologic Side Effects

• Thrombocytopenia
• Anemia
• Neutropenia
• Lymphopenia
• Leukopenia

🩺 Special Precautions & Monitoring

Congestive Heart Failure

Monitor patients for signs and symptoms of heart failure and manage clinically when necessary.

Hypertension

Blood pressure should be monitored regularly and treated appropriately.

Pancreatitis

Serum lipase levels should be monitored monthly. Treatment interruption or discontinuation may be required.

Hemorrhage

Interrupt treatment in cases of serious bleeding.

Fluid Retention

Monitor for edema or fluid accumulation. Dose interruption, reduction, or discontinuation may be necessary.

Arrhythmias

Patients should be monitored for symptoms of cardiac rhythm abnormalities.

Bone Marrow Suppression

Thrombocytopenia, neutropenia, and anemia may require treatment interruption or dose reduction.

• Complete blood counts should be monitored every 2 weeks for the first 3 months, then monthly or as clinically indicated
• Interrupt treatment if ANC <1000/mm³ or platelet count <50,000/mm³

Tumor Lysis Syndrome

Ensure adequate hydration and correct elevated uric acid levels before starting treatment.

Impaired Wound Healing & Gastrointestinal Perforation

Temporary interruption may be required before major surgery.

Embryo-Fetal Toxicity

Ponatinib may cause fetal harm. Women should be informed about potential risks during pregnancy.